Gefitinib Reactions 1680, p150 - 2 Dec 2017 Bleeding during surgery: case report A 60-year-old woman developed fatal bleeding during treatment with gefitinib. The woman, who had been diagnosed with stage IIIA nonsmall cell lung carcinoma 8 years previously, was hospitalised with complaints of chest pain. She had been receiving chemotherapy with gefitinib [route and dosage not stated] along with aspirin, metoprolol, iron and vitamin- B12-analogues [vitamin B12]. After admission, her chest radiograph revealed left perihilar parenchymal scars, surgical clips and postoperative changes in the chest. Subsequently, she underwent exercise nuclear stress test which revealed indeterminate ECG changes and a small artifactual anteroseptal wall defect. After undergoing the stress test, she complained of retrosternal chest pain. Her serum troponin level was noted to be increased. Subsequently, coronary angiography revealed 90% stenosis of the left main coronary artery ostium, which was described as radiation induced coronary artery disease (RICAD). A coronary artery bypass graft/surgical revascularisation was planned. Overnight, she suffered with intense anginal chest pain without any elevation in cardiac enzymes. Therefore, the surgery was initiated. During the surgery, dense adhesions surrounding the heart were observed. She developed severe bleeding from the adhesions [duration of treatment to reaction onset not stated]. The woman underwent aggressive transfusion of RBCs and platelets. However, the bleeding was uncontrollable and she died during surgery. Author comment: "[O]ur patient was receiving the gefitinib, a chemotherapeutic agent which decreases platelet function via prostaglandin and thrombaxene and increases the bleeding risk." "She went to the operating room for CABG due to recurrent unstable angina but developed fatal bleeding related to side effects of both radiation and chemotherapy." Alsara O, et al. Isolated left main coronary artery stenosis after thoracic radiation therapy: To operate or not to operate. Case Reports in Medicine 2013: 2013. Available from: URL: - USA 803284031 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial